🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Save the date Bogotá! Heme-onc Andres Gomez Laura Korin Lia Palomba Alexandra Gomez A. Fundación Santa Fe de Bogotá Facultad de Medicina - Universidad de los Andes Women in Lymphoma - [email protected]

Aprendiendo de la experiencia Méxicana para TPH y CAR ambulatorio The Innovation | Medicine LABMT Gracias Andres Gomez

Learning and reconnecting with my mentor Lia Palomba Women in Lymphoma - [email protected] Memorial Sloan Kettering Cancer Center Fundación Santa Fe de Bogotá Facultad de Medicina - Universidad de los Andes

Gracias por todo lo que haces por la ciencia/ linfoma en LATAM Laura Korin-are we ready for BTKi on the frontline in LATAM? Guilherme Perini, MD

Amiga, consejera, profesora . Próximo año tenerte en casa, gracias Alexandra Gomez A. orgullo Facultad de Medicina - Universidad de los Andes Memorial Sloan Kettering Cancer Center EMR pre TPH: nos cambia el manejo?

CONGRESS | #SOHO2024 @gilles_salles Memorial Sloan Kettering Cancer Center discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.

Unexpected use of CD19-CAR-T cells: Point-of-care CD19-directed CAR-T cells in AML expressing CD19. 4/6 patients achieved a CR! Arnon Nagler Sheba Medical Center #CART #AML sciencedirect.com/science/articl…

#Hematology CNS bridging #radiotherapy achieves rapid cytoreduction before #CARTcell therapy for aggressive B-cell #lymphomas | ⁦Blood Advances⁩ | American Society of Hematology ⁦ASH⁩ #lymsm #radonc ashpublications.org/bloodadvances/…

Looking forward to this exciting event in Bogota!

And no. 1 #PeriniPicks for #ASH24 could not be other: ash.confex.com/ash/2024/webpr… "... ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients"

A phase 1 study led by Jae Park evaluated a novel CAR T cell therapy for people with large B-cell #lymphoma. Of 28 trial participants, the overall response rate was 82% and complete response was 71%. Patients did well on low doses that minimized side effects. #lymsm

La cuenta regresiva avanza y ya estamos a 1 mes de esta oportunidad de aprender y compartir en torno a las neoplasias linfoproliferativas. Ven a vivir la experiencia! #LEx25 #LExMeet25

Correspondence: Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma nej.md/4lS7kfe #Hematology

Can we increase the chances of achieving CR in R/R DLBCL pts with ADCs or bispecific antibodies in combination with chemo? I think so! This is still a clinical unmet need considering lack of global cart access. Happy to have some of these trials running in 🇦🇷. #EHA25 #icml2025

Prognostic factors in cart cell therapy in R/R DLBCL. Yes!, I confess that I broke my own rule of not attending cart sessions until they are available in my country but it was worth it! #ICML2025 #ICML18

En Colombia siguen aumentando los casos de infección respiratoria aguda, especialmente en mayores de 60 años. 💉 La vacunación contra COVID-19, influenza y neumococo es clave para protegernos. #SaludPública #Vacunación #Colombia

Segunda sesión de nuestro 1 evento Fundación CTIC con el aval de Asociación Colombiana de Hematología y Oncología #hematologiaCTIC Leucemia Mieloide Aguda. Con la Dra Claudia Sossa, la Dra María José López y el Dr Eytan Stein.

That feeling when 7+ years of work lands on the front page of NEJM—and one of the people I respect most, Kohei shitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn Memorial Sloan Kettering Cancer Center